<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19945">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01823211</url>
  </required_header>
  <id_info>
    <org_study_id>FNO-KVO-2</org_study_id>
    <secondary_id>Plasek680-2</secondary_id>
    <nct_id>NCT01823211</nct_id>
  </id_info>
  <brief_title>Profitability Trial in Primary Preventive Implantable Cardioverter-defibrillator Recipients</brief_title>
  <acronym>HAPPIER</acronym>
  <official_title>Heart Rate Variability, Microvolt T-wave Alternans and Cardiac Magnetic Resonance Imaging Analysis in Primary Preventive ImplantablE Cardioverter-defibrillator Recipients Profitability Trial - HAPPIER Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Olomouc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <authority>Czech Republic: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is further risk stratification of patients receiving implantable
      cardioverter-defibrillator in primary prevention of sudden cardiac death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current criteria for risk stratification of patients in risk of sudden cardiac death are
      mainly based on left ventricular ejection fraction and NYHA class. This criteria are too
      robust, approximately 2/3 of ICD recipients do not profit from this treatment in the
      following 5 years, especially those with non-ischaemic cardiomyopathy. We plan to
      sub-stratify this group of patients with both ischaemic and non-ischaemic cardiomyopathy by:
      non-linear heart rate variability analysis, microvolt T-wave alternans, QRT-T angle and
      character and amount of left ventricular scarring assessed by magnetic resonance imaging.
      Pre-implantation values will be correlated with numbers and character of ICD therapy (both
      anti-tachycardial pacing and ICD discharge). The results may allow to decrease the number of
      patients, who do not profit from ICD treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>ventricular tachyarrhytmia</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>ventricular tachycardia equal or &gt; 250/min,ventricular fibrillation, arrhythmic storm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sudden cardiac death</measure>
    <time_frame>36-months</time_frame>
    <safety_issue>No</safety_issue>
    <description>death in 24-hours after symptom onset</description>
  </secondary_outcome>
  <other_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>36-months</time_frame>
    <safety_issue>No</safety_issue>
    <description>mortality from both cardiovascular and non-cardiovascular cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>36-months</time_frame>
    <safety_issue>No</safety_issue>
    <description>death from strictly cardiovascular cause</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Ischaemic Cardiomyopathy</condition>
  <condition>Non-ischaemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>ischaemic cardiomyopathy</arm_group_label>
    <description>EP (Electrophysiology) study,magnetic resonance with LGE (Late gadolinium enhancement), ICD implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-ischaemic cardiomyopathy</arm_group_label>
    <description>EP study,magnetic resonance imaging with LGE, ICD implantation</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Heart-failure clinic,primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LVD (left ventricular dysfunction) d/t MI (Myocardial infarction), LVEF 30% or less,
             NYHA (New York Heart association class) II, III

          -  LVD d/t MI, LVEF 30% to 35%, NYHA II, III

          -  LVD d/t MI, LVEF 30% to 40%, NSVT, positive EP study

          -  LVD d/t MI, LVEF 30% or less, NYHA I

          -  NICM (non-ischaemic cardiomyopathy), LVEF 30% or less, NYHA II, III

          -  NICM, LVEF 30% to 35%, NYHA II, III

          -  NICM, LVEF 30% or less, NYHA I

          -  signed informed consent

        Exclusion Criteria:

          -  metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in
             their brain, cannot have an MRI scan since the magnetic field may dislodge the metal

          -  severe claustrophobia may not be able to tolerate an MRI scan

          -  heart rhythm device in place before enrollment

          -  atrial fibrillation in time of enrollment

          -  ICD implantation indicated from secondary prevention of SCD (sudden cardiac death)

          -  NYHA or CCS class IV

          -  PCI or CABG in last 3 months

          -  CMP/TIA in last 3 months

          -  syncope of unknown etiology
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiri Plasek, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Cardiology,University hospital Ostrava</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Milos Taborsky, MD, PhD, FESC</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology,University Hospital Olomouc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lubos Krivan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology,University Hospital Brno-Bohunice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ondrej Moravec, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology,University Hospital Olomouc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vaclav Prochazka, MD,PhD,MSc</last_name>
    <phone>+420597372510</phone>
    <email>vaclav.prochazka@fno.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brno University Hospital</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jindrich Spinar, MD,PhD,FESC</last_name>
      <phone>+420 532 23 2601</phone>
      <email>jspinar@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Lubos Krivan, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milos Taborsky, MD,PhD,FESC,MBA</last_name>
      <phone>+420 588 443 201</phone>
      <email>1.interna@fnol.cz</email>
    </contact>
    <investigator>
      <last_name>Ondrej Moravec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaclav Prochazka, MD,PhD,MSc</last_name>
      <phone>+420597372510</phone>
      <email>vaclav.prochazka@fno.cz</email>
    </contact>
    <investigator>
      <last_name>Jiri Plasek, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Sipula, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <link>
    <url>http://happiertrial.org</url>
    <description>Trial database</description>
  </link>
  <reference>
    <citation>Seely AJ, Macklem PT. Complex systems and the technology of variability analysis. Crit Care. 2004 Dec;8(6):R367-84. Epub 2004 Sep 22. Review.</citation>
    <PMID>15566580</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 27, 2013</lastchanged_date>
  <firstreceived_date>March 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Ostrava</investigator_affiliation>
    <investigator_full_name>Vaclav Prochazka, MD, PhD. MSc</investigator_full_name>
    <investigator_title>MD,PhD,MSc</investigator_title>
  </responsible_party>
  <keyword>ICD (Implantable cardioverter-defibrillator)</keyword>
  <keyword>Heart rate variability</keyword>
  <keyword>MTWA (Microvolt T-alternans)</keyword>
  <keyword>Magnetic resonance imaging (MRI)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
